Skip to main
APLM
APLM logo

Apollomics Inc (APLM) Stock Forecast & Price Target

Apollomics Inc (APLM) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apollomics Inc., a clinical-stage biopharmaceutical company, showcases promising advancements in oncology therapies, particularly with vebreltinib (APL-101) and uproleselan (APL-106). Vebreltinib has demonstrated an impressive 66.7% objective response rate (ORR) in its Phase 1/2 trials, outperforming comparable MET inhibitors, which have shown ORRs of 40-55%, thereby indicating its potential to address significant unmet medical needs in MET-amplified cancers. Furthermore, uproleselan's ability to enhance chemotherapy efficacy in acute myeloid leukemia through the blockade of E-selectin presents additional avenues for successful treatment options, contributing positively to Apollomics's overall growth prospects.

Bears say

Apollomics Inc. is projected to experience significant net losses, with expectations of $2.11 per share for 2023 and $0.66 per share for 2024, raising concerns regarding its financial health. The company faces numerous risks, including potential negative clinical data, slower development timelines, setbacks in clinical studies, and the possibility of regulatory approval failures, which could hinder its growth and profitability. Additionally, the company's reliance on equity financing and the risk of dilution, coupled with a complex corporate structure, contribute to a challenging outlook for investors.

Apollomics Inc (APLM) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apollomics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apollomics Inc (APLM) Forecast

Analysts have given Apollomics Inc (APLM) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Apollomics Inc (APLM) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apollomics Inc (APLM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.